Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Breast Neoplasms

Recurrence

Breast Diseases

Skin Diseases

All Drugs and Chemicals

Antineoplastic Agents

Micronutrients

Vasodilator Agents

Lipid Regulating Agents

Hematinics

Vitamins

Antibodies

Antibodies, Monoclonal

Paclitaxel

Bevacizumab

Albumin-Bound Paclitaxel

Angiogenesis Inhibitors

Immunoglobulins

Imetelstat

Motesanib diphosphate

Niacinamide

Niacin

Nicotinic Acids

Tubulin Modulators

Antimitotic Agents

Antineoplastic Agents, Immunological

Growth Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Trace Elements

Nicotinamide

Nicotinic Acid

Vitamin B3

Folate

Vitamin B9

AMG 706 placebo

Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.

AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.

AMG 706

Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.

To determine if treatment with paclitaxel plus AMG 706 is superior to paclitaxel plus AMG 706 placebo in subjects with HER2 negative locally recurrent or metastatic breast cancer. Also to estimate differences between treatment with paclitaxel plus AMG 706 and paclitaxel plus bevacizumab.

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination With Paclitaxel, or Open-Label Bevacizumab in Combination With Paclitaxel, as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer

Amgen

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer	NCT00356681	Breast Neoplasm... Breast Tumors Breast Cancer Locally Recurre...	AMG 706 placebo Bevacizumab AMG 706 Paclitaxel	18 Years -	Amgen
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer	NCT00356681	Breast Neoplasm... Breast Tumors Breast Cancer Locally Recurre...	AMG 706 placebo Bevacizumab AMG 706 Paclitaxel	18 Years -	Amgen

Spots Global Cancer Trial Database for amg 706 placebo